Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples